PedvaxHIB

 

Topic mentions per year

Topic mentions per year

1990-2016
02419902016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Open-label, multicenter, randomized study (NCT00289913) evaluated immunogenicity, safety, and tolerability of Vaqta (hepatitis A… (More)
Is this relevant?
2011
2011
BACKGROUND In December 2007, Merck & Co, Inc, initiated a voluntary recall of 10 lots of PedvaxHIB, and 2 lots of COMVAX when the… (More)
Is this relevant?
2005
2005
PedvaxHIB is a pediatric vaccine that protects children from severe disease caused by the gram-negative bacterium Haemophilus… (More)
Is this relevant?
2004
2004
We report an evaluation of the short-term safety of a pediatric bivalent combination vaccine containing RECOMBIVAXHB and Liquid… (More)
Is this relevant?
2002
2002
BACKGROUND In a previous clinical trial comparing COMVAX with its monovalent components, PedvaxHIB and RECOMBIVAX HB, one of 92… (More)
Is this relevant?
2001
2001
The Northern Territory of Australia has had historically very high incidence rates of invasive Haemophilus influenzae type b… (More)
Is this relevant?
1997
1997
OBJECTIVE To determine the safety and immunogenicity of concurrent administration of measles-mumps-rubella-varicella vaccine… (More)
Is this relevant?
1997
1997
OBJECTIVE To assess the safety, tolerability and immunogenicity of COMVAX, a liquid, bivalent Haemophilus influenzae type b… (More)
Is this relevant?
1994
1994
Haemophilus influenzae type b (Hib) is a major cause of serious childhood bacterial infections. Before 1989 Alaska Native infants… (More)
Is this relevant?
1990
1990
Although systemic infections caused by Haemophilus influenzae type b occur worldwide, detailed epidemiologic data are available… (More)
  • table 1
  • table 2
  • table 4
  • table 5
Is this relevant?